Table 2. Number of Lymph Nodes Removed by Type of Surgery.
| No. of lymph nodes removed | Type of surgery | Difference (95% CI)a | |
|---|---|---|---|
| Arm A: ALND (n = 250) | Arm B: no ALND (n = 250) | ||
| Overall, median (IQR) | |||
| Total | 18 (13-24) | 5 (3-7) | 12 (11-13) |
| Positive | 4 (2-8) | 2 (1-4) | 1 (1-2) |
| Negative | 12 (8-16) | 2 (1-4) | 9 (8-10) |
| Upfront surgery setting: HR+/ERBB2−, median (IQR) | |||
| Total No. | 151 | 145 | NA |
| Total | 19 (14-26) | 5 (4-8) | 14 (12-15) |
| Positive | 4 (2-9) | 3 (1-4) | 2 (1-2) |
| Negative | 12 (9-18) | 2 (1-4) | 10 (9-11) |
| Neoadjuvant chemotherapy,b median (IQR) | |||
| Total No. | 77 | 74 | NA |
| Total | 15 (12-19) | 4 (3-7) | 10 (9-12) |
| Positive | 2 (1-5) | 2 (1-3) | 1 (0-1) |
| Negative | 12 (7-15) | 2 (1-4) | 9 (7-11) |
Abbreviations: ALND, axillary lymph node dissection; ERBB2−, Erb-B2 receptor tyrosine kinase 2 negative (formerly HER2 or HER2/neu); HR+, hormone receptor positive; NA, not applicable.
a
Hodges-Lehmann estimator.
b
Fourteen patients had other neoadjuvant therapy than chemotherapy.